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Primary hyperparathyroidism is a disorder, in which parathormone is secreted excessively and it is associated with hypercalcemia. The cause 
of primary hyperparathyroidism is seen in 85% of 
parathyroid adenoma cases, in 4% of multiple adenoma 
cases, and in 10% of hyperplasia cases. The most common 
cause of hypercalcemia is hyperparathyroidism (1). 
Hypercalcemia is rare in pregnancy and the most common 
cause of it is primary hyperparathyroidism. In general, 
early primary hyperparathyroidism is rare in pregnancy. 
The incidence of primary hyperparathyroidism in 
pregnant women is estimated to be 8 per 100 000 per year 
(2). As primary hyperparathyroidism is asymptomatic 
in 80% of pregnant patients, it is difficult to diagnose it. 
Patients with hyperparathyroidism in the asymptomatic 
stage usually remain undiagnosed. When it becomes 
symptomatic, the most common symptoms would be 
gastrointestinal, musculoskeletal, and urinary tract 
symptoms. Hyperparathyroidism during pregnancy in 
more than two-thirds of cases causes significant morbidity 
in mothers and embryo. 
Embryo problems include increased probability of 
abortion, severe intrauterine growth disturbance, 
and stillbirth. As parathyroid gland of the embryo is 
suppressed in pregnancy, after delivery at time of closing 
the umbilical cord, the calcium of the embryo blood is 
reduced progressively and the suppressed parathyroid 
gland of embryo might not be able to respond properly 
and the infant would suffer from seizure caused by 
hypocalcaemia and require long-term care. If mild to 
moderate hyperparathyroidism is not diagnosed during 
pregnancy, by observing the hypocalcaemia in the infant, 
the mother should be evaluated in this regard. Classic 
symptoms of hyperparathyroidism such as bone pain, 
bone fracture and kidney stone are more rarely seen during 
pregnancy in mother, and many patients are diagnosed 
with routine tests and blood calcium measurement.
Complications on hypercalcemia such as nausea, 
vomiting, lethargy and drowsiness might be attributed 
to hyperemesis gravidarum, unless these symptoms are 
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examined due to severity. As calcium passes through the 
placenta during pregnancy and enters the bloodstream 
of embryo, hypercalcemia might not be severe. However, 
hypercalcemia may be exacerbated by PTH-related 
peptide (PTHrP) due to excessive breastfeeding after 
delivery. 
Parathormone is not measured routinely in pregnant 
women. Diagnosis of hyperparathyroidism during 
pregnancy with high levels of calcium and serum PTH 
and the absence of other causes of hypercalcemia 
should be considered. Neck ultrasound is a selective 
imaging method during pregnancy to determine the 
location of the parathyroid adenoma. It has a sensitivity 
of 69% and a specificity of 94%. Most of parathyroid 
adenomas are located in the lower parathyroid gland. CT 
scan and scintigraphy during pregnancy is prohibited 
(3,4). In pregnancy, the neck MRI can be performed 
without any risk. Patients should be followed up when 
asymptomatic and serum calcium is lower than 12 mg/
dL. It is recommended to use high levels of fluids and 
low levels of calcium. A symptomatic patient with serum 
calcium higher than 12 mg/dL requires accurate heart 
monitoring, and in addition to receiving adequate fluids, 
prescribing diuretics, bisphosphonates and calcitonin 
might be needed. If the clinical signs and hypercalcemia 
were not improved in the patients by these measures, an 
emergency parathyroidectomy in the second trimester 
(when organogenesis has been occurred and risk of early 
delivery caused by anesthesia is low) should be considered. 
Surgery in the third trimester is associated with high risk 
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of preterm delivery (3,4).
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